Post-ERCP Pancreatitis Trends in the United States

An analysis of nationwide inpatient data yields some unexpected findings.

Despite advances in endoscope technology, endoscopic technique, and the widespread adoption of prophylactic pharmacologic agents, pancreatitis remains the most common severe adverse event following endoscopic retrograde cholangiopancreatography (ERCP). Post-ERCP pancreatitis (PEP) also remains a significant cause of endoscopy-related lawsuits.

In a recent retrospective study, investigators assessed trends in PEP incidence and mortality in the United States using nationwide inpatient admissions data. Among over 1.2 million patients undergoing ERCP between 2011 through 2017, findings were as follows:

The overall rate of PEP was 4.5% (comparable to rates in prior large analyses).
PEP admissions increased 13% between 2011 and 2017.
Among patients w…

Reviewing Author

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Post-ERCP Pancreatitis Trends in the United States

Topics

Reviewing Author